The global cell banking outsourcing market size was computed at USD 10.57 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 16.34% from 2023 to 2030. Rising advancement of the cryopreservation and cell bank preparation methodologies, increasing adoption of stem cell therapies, and growing demand for monoclonal antibodies along with effective biopharmaceuticals are the major factors, driving growth of the market. According to CellTrials.org global enrolments of new trials in advanced cell therapy were up almost 30% in the first quarter of 2020. Most of the rise can be associated with cell therapy efforts for treating COVID-19, and over half of those trials for COVID-19 employ umbilical cord MSCs. Hence, the pandemic has created a new market for those companies which are engaged in the manufacturing of MSCs products from donated birth tissues, hence may contribute to the market growth, post pandemic.
Moreover, many of these manufacturers have applied for COVID-19 EUA from the FDA and are partnering with local hospitals to treat COVID-19 patients. For instance, in September 2021, Life Cell’s Mesocel received approval for a clinical trial from DCGI; therapy derived MSC of the umbilical cord tissue set to treat patients with pneumonia, COVID-19, and acute respiratory distress.
The presence of favorable government initiatives for the development of stable cell lines, as well as the introduction of new technology for cell line storage and characterization, are among the critical factors expected to drive market growth in the forecast period. For instance, In December 2021, ‘Vineti’ and ‘Be The Match BioTherapies’ collaborated to develop an integrated supply chain management solution for gene and cell therapy. Such initiatives and collaborations are anticipated to drive growth during the forecast period.
Furthermore, the key players in the market are also involved in research collaborations, in order to reprogram newborn stem cells from umbilical cord blood as well as umbilical cord tissue into iPSCs. These collaborations are also expected to drive the growth of market over the forecast period. For instance, In May 2021, Opsis Therapeutics, FUJIFILM Cellular Dynamics, and Blue Rock Therapeutics entered into strategic research and development to create cell therapies to cure eye diseases. These companies will use their expertise to develop off-the-shelf iPSCs to cure ocular diseases.
According to a recent study led by the Indiana University School of Medicine in March 2022, human-induced pluripotent stem cells improve visual acuity and vascular health. This study is being done in collaboration with Indiana University School of Medicine and five other institutions to investigate a novel regenerative medicine approach to better manage the vascular health complications associated with type 2 diabetes. Such research activities are expected to boost stem cell banking. Additionally, research for the introduction of cry protective agents to preserve the stability of the tissues during cryopreservation is expected to drive the market.
Master cell banking accounted for the largest share of 64.5% in 2022, as their preparation is a prerequisite for the production and usage of working cell banks. They are preserved for a significantly longer duration, which also attracts the application of high-grade cryopreservation methodologies and equipment thereby further expanding the revenue base for this segment.
Furthermore, master cell banks find applicability in various research and development perspectives for stem cell therapy and gene therapy. Rising incidences of autoimmune diseases and cancer that can be treated by the use of therapies in combination with regenerative medicine is a key factor expected to fuel the growth of this segment, during the forecast period.
Stem cells segment dominated the market with a share of 52.4% in 2022. Stem cells are obtained from cord blood, embryonic, adult, dental, and IPS cells, while non-stem include somatic cells preserved for applications such as tissue engineering and IPS cell development. An increase in research and development activities associated with the applications of stem cells drives the segment growth. For instance, in February 2021, American CryoStem collaborated with BioTherapeutic Labs Corp for the research and development in stem cell.
Cord cell banking accounted for a significant market share with respect to revenue in 2022 and their large share can be attributed to the rise in the number of cord blood banks and banking services across the globe. Cord blood provides significant advantages, which include serving as a source of hematopoietic stem cells, donor convenience, minimized risk of graft versus host diseases, low risk of viral contamination and immediate availability.
Based on phase, the market is segmented into bank storage, bank characterization and testing, and bank preparation. Among these, storage accounted for the largest share of 43.7% in 2022 owing to sophisticated preservation needs which are essential for proper maintenance of either master or working banks. Additionally, technologically advanced cryopreservation techniques are expected to fuel the growth of this market throughout the forecast period.
Bank storage in cell banking encompasses the preservation of both master and working banking and their respective safety testing. Bank characterization & testing is expected to witness lucrative growth during the forecast period owing to the presence of market players that are involved in providing outsourcing services for bank characterization & testing to different hospitals and clinical research organizations. For instance, Creative Biogene offers a wide-ranging bank characterization service to the customers to safeguard the biosafety and control of biotechnological and biological products.
North America dominated the market and accounted for the largest market share of 40.6% in 2022, owing to the presence of extensive R&D laboratories and rising incidences of metabolic disorders such as Parkinson’s, Alzheimer’s, and various other types of cancers, which can be treated by gene therapy. The steep rate of increase in the establishment of banking services, which is a sign of rapid change, also contributes to the organizational diversity in the North American healthcare system.
Asia Pacific is expected to grow at a fastest CAGR of 19.58% during 2023 - 2030. This exponential CAGR is credited to the presence of pharmaceutical companies, which are focusing their priorities on the large and relatively untapped populations in Asia.
Low cost of clinical trials and high investments in biotechnology sector is expected to fuel the market growth of this regional market. In May 2022, International Conference on Stem Cell Research and Therapy was held in China, aiming to give a platform for academicians, researchers, industrial professionals to present their research and discuss developments, and advancements in stem cell. Such initiatives by private and government organizations to discuss and support stem cell research is anticipated to help the market grow in this region.
Key players in this market are implementing various strategies including partnerships through mergers & acquisitions, geographical expansion, and strategic collaborations to increase their market presence. For instance, in May 2023 panCELLa and BioCentriq, Inc. formed a research agreement to evaluate the ability of panCELLa's genetically engineered iPSC-derived, feeder cells to activate and positively impact the expansion rate, total yield, and potency of manufactured NK cells. Some of the key players in the global cell banking outsourcing market include:
Bio Outsource (Sartorious)
BSL Bioservice
Cryo-Cell International, Inc
Charles River Laboratories
LifeCell
GBI
Lonza
SGS Société Générale de Surveillance SA
Perfectus Biomed Limited
Report Attribute |
Details |
Market size value in 2023 |
USD 12.34 billion |
Revenue forecast in 2030 |
USD 35.59 billion |
Growth rate |
CAGR of 16.34% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Report updated |
June 2023 |
Quantitative units |
Revenue in USD million/billion, and CAGR from 2023 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Type, cell type, phase, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
Country scope |
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
Bio Outsource (Sartorious), BSL Bioservice, Cryo-Cell International, Inc., Charles River Laboratories, LifeCell, GBI, Lonza, SGS Société Générale de Surveillance SA, Perfectus Biomed Limited |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the global cell banking outsourcing market report on the basis of type, cell type, phase, and region.
Type Outlook (Revenue, USD Million, 2018 - 2030)
Master Cell Banking
Working Cell Banking
Viral Cell Banking
Cell Type Outlook (Revenue, USD Million, 2018 - 2030)
Stem Cell
Cord Cell Banking
Embryonic Stem Cell Banking
Adult Stem Cell Banking
Dental Stem Cell Banking
IPS Stem Cell Banking
Non-stem Cell
Phase Outlook (Revenue, USD Million, 2018 - 2030)
Bank Storage
Master Cell Bank Storage
Working Cell Bank Storage
Cell Storage Stability Testing
Bank Characterization & Testing
Safety Testing
Viral Cell Banks
Microbial Cell Banks
Gene Expression Testing
Karyology Testing
Gene Sequencing Testing
Bank Preparation
Master Cell Bank Preparation
Working Cell Bank Preparation
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Thailand
Australia
Latin America
Brazil
Mexico
Argentina
Middle East and Africa (MEA)
South Africa
Saudi Arabia
UAE
Kuwait
b. The global cell banking outsourcing market size was estimated at USD 10.57 billion in 2022 and is expected to reach USD 12.34 billion in 2023.
b. The global cell banking outsourcing market is expected to grow at a compound annual growth rate of 16.34% from 2023 to 2030 to reach USD 35.59 billion by 2030.
b. North America dominated the cell banking outsourcing market with a share of 40.6% in 2022. This is attributable to rising healthcare awareness coupled with constant research and development initiatives in the region pertaining cell freezing, retrieval, and analysis.
b. Some key players operating in the cell banking outsourcing market include Bio Outsource (Sartorious), BSL Bioservice, Cryo-Cell International, Inc., Charles River Laboratories, LifeCell, GBI, Lonza, SGS Société Générale de Surveillance SA, Perfectus Biomed Limited.
b. Key factors that are driving the cell banking outsourcing market growth include increasing investment in expanding cell banking capabilities to meet the market demands coupled with increasing genomics and molecular R&D that requires cell specimens for research activities
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."